Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)
NCT ID: NCT04866680
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
165 participants
INTERVENTIONAL
2023-01-31
2029-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
NCT02828202
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors
NCT02342158
Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
NCT01336270
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124
French Clinical Datbase of Melanoma Patients (RIC-Mel)
NCT03315468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Personalized Circulating DNA follow-up
FFPE tissue sample + blood sample (20ml)
Personalized Circulating DNA follow-up
FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Personalized Circulating DNA follow-up
FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.
Exclusion Criteria
* woman who is pregnant, likely to be pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Cancérologie de Lorraine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Jean Minjoz
Besançon, , France
CGFL
Dijon, , France
Chu Dijon
Dijon, , France
Chru Lille
Lille, , France
Ghr Mulhouse Sud Alsace
Mulhouse, , France
Institut Godinot
Reims, , France
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, , France
Chru Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01904-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.